Compare
Neonc Technologies Holdings, Inc. vs Altimmune, Inc. vs Lyell Immunopharma, Inc. vs HCW Biologics Inc.
| Latest fiscal year | Neonc Technologies Holdings, Inc. NTHI | Altimmune, Inc. ALT | Lyell Immunopharma, Inc. LYEL | HCW Biologics Inc. HCWB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $40.0K | $41.0K | $36.0K | $54.2K |
| Revenue growth (YoY) | -51.8% | +105.0% | -41.0% | -97.9% |
| Gross margin | n/a | n/a | n/a | 20.0% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$62.15M | -$88.09M | -$274.45M | -$7.96M |
| EPS (Diluted) | -$3.20 | -$1.00 | -$16.06 | -$10.63 |
| Operating cash flow | -$20.36M | -$67.53M | -$150.02M | -$13.39M |
| Free cash flow | -$20.86M | -$67.55M | -$150.80M | -$13.39M |
| Cash & equivalents | $58.7K | $43.76M | $60.18M | $1.95M |
| Total assets | $2.82M | $279.93M | $340.05M | $24.52M |
| Total liabilities | $20.33M | $55.04M | $91.85M | $21.76M |
| Shareholders' equity | -$17.51M | $224.89M | $248.20M | $2.76M |
| Return on year-end equity | n/a | -39.2% | -110.6% | -287.9% |
| Shares outstanding | 21.99M | 110.88M | 21.25M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Neonc Technologies Holdings, Inc. | Altimmune, Inc. | Lyell Immunopharma, Inc. | HCW Biologics Inc. |
|---|---|---|---|---|
| Latest | $40.0K Ended 2025-12-31 | $41.0K Ended 2025-12-31 | $36.0K Ended 2025-12-31 | $54.2K Ended 2025-12-31 |
| 1 year earlier | $83.0K Ended 2024-12-31 | $20.0K Ended 2024-12-31 | $61.0K Ended 2024-12-31 | $2.57M Ended 2024-12-31 |
| 2 years earlier | n/a | $426.0K Ended 2023-12-31 | $130.0K Ended 2023-12-31 | $2.84M Ended 2023-12-31 |
| 3 years earlier | n/a | -$68.0K Ended 2022-12-31 | $84.68M Ended 2022-12-31 | $6.72M Ended 2022-12-31 |
| 4 years earlier | n/a | $4.41M Ended 2021-12-31 | $10.65M Ended 2021-12-31 | $0 Ended 2021-12-31 |